Tempus AI (NASDAQ: TEM) shares rose 7.30% to $49.34 following the announcement that 31 abstracts were accepted for presentation at the AACR Annual Meeting 2026. The presentations highlight emerging biomarkers and real-world evidence in cancer treatment, including studies on MSI-related gene fusions in colorectal cancer, KMT2C mutations linked to platinum therapy benefits, and SCLC subtype variability. However, Jefferies initiated coverage with an Underperform rating and $35 price target.

Tempus AI announced an expanded multi-year collaboration with Merck to accelerate AI-driven precision medicine development. The partnership will leverage Tempus' data library and Lens Platform to identify novel precision biomarkers for oncology and other therapeutic areas. Despite the positive deal announcement, Tempus shares declined 1.56% amid broader market sell-offs affecting the S&P 500 and Nasdaq.

Hospital networks are increasingly adopting AI-enhanced cardiac imaging technologies to reduce costs and improve patient outcomes. The AI medical imaging market is projected to reach nearly $20 billion by 2033, with echocardiography expected to grow to $2.64 billion by 2030. Key players including VentriPoint Diagnostics, Butterfly Network, Tempus AI, RadNet, and GE HealthCare are expanding their deployments across healthcare systems, with several reporting strong revenue growth and positive financial metrics.

The week saw escalating US-Taiwan trade tensions following the Supreme Court's strike-down of Trump's emergency tariff authority, prompting new tariff rollouts. Major tech companies reported mixed earnings results, with Amazon announcing a $12B US investment and Apple shifting Mac Mini production to Texas. AI developments dominated headlines with OpenAI's Frontier Alliances program, Microsoft's Sovereign Cloud expansion, and concerns over Chinese AI capabilities. The EV market showed growth with new models from Tesla competitors, while several companies announced restructuring efforts.

Cathie Wood's Ark Invest added to positions in AMD, Tesla, and Tempus AI on Wednesday amid market volatility. AMD delivered strong earnings with 34% revenue growth and beat profit expectations, but shares fell 17% due to disappointing guidance. Tesla is pivoting toward robotics production as EV sales stall. Tempus AI, focused on oncology AI solutions, has seen shares cut in half from October highs despite 84% revenue growth.

U.S. hospitals are rapidly adopting AI and healthcare technology, with 71% now using predictive AI as of 2024, up from 66% in 2023. Leading healthcare tech companies like Tempus AI, OpenEvidence, Sword Health, and Huma are securing significant funding and valuations, while clinical documentation automation has reached 100% adoption in surveyed U.S. health systems. The global AI in healthcare market is projected to grow from $37.98 billion in 2025 to $928.18 billion by 2035 at a CAGR of 37.66%.

Nancy Pelosi and her husband Paul filed their first 2026 financial disclosures, revealing bullish stock moves in major tech companies including Nvidia, Alphabet, and Amazon through exercised call options. Their portfolio of five stocks achieved approximately 41.7% returns over one year, double the S&P 500 performance, demonstrating their successful long-term investing track record focused on AI and technology sectors.

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.

Ark Invest unveiled its 'big ideas' for 2026 through cryptic ARKmoji images, challenging users to interpret six investment themes: AI Agents, Genomics, Space Race (reusable rockets), Cryptocurrencies/Tokenization, Robotics, and The Great Acceleration. The firm highlighted portfolio holdings aligned with each theme, spanning multiple sectors from biotech to defense and space technology.

Four high-growth stocks are positioned to deliver explosive earnings growth this season: Robinhood (HOOD) with 51.1% EPS growth expected, Reddit (RDDT) with 240.4% EPS growth, IREN with 104.8% revenue growth, and Tempus AI (TEM) with 80.1% revenue growth. All four companies are benefiting from strong industry tailwinds including AI adoption, crypto trading expansion, and healthcare innovation.

Tempus AI stock rose over 4% after issuing an upbeat sales forecast, projecting 83% year-over-year revenue growth to $1.27 billion for the full year. The healthcare AI company announced record contract value of $1.1 billion and a net revenue retention of 126%, driven by strong diagnostics sales growth of 121% and partnerships with major pharmaceutical companies including Pfizer, Novartis, and Eli Lilly.

Tempus AI (NASDAQ: TEM) stock rose on Monday following the release of preliminary fourth-quarter and full-year 2025 results showing $1.27 billion in revenue with 83% year-over-year growth. The company also announced two major strategic partnerships: a multi-year collaboration with NYU Langone Health to advance cancer care through molecular profiling, and a contract with Northwestern Medicine to broaden access to genomic testing for cancer patients.